Cdc20 overexpression is involved in temozolomide-resistant glioma cells with epithelial-mesenchymal transition

References

• Ohgaki H, Kleihues P. Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Science. 2009;100:2235–41. doi:10.1111/j.1349-7006.2009.01308.x. PMID:19737147.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA: A cancer. Journal for Clinicians. 2017;67:7–30. doi:10.3322/caac.21387.
   PubMed Web of Science ®Google Scholar
• Aibaidula A, Lu JF, Wu JS, Zou HJ, Chen H, Wang YQ, Qin ZY, Yao Y, Gong Y, Che XM, et al. Establishment and maintenance of a standardized glioma tissue bank: Huashan experience. Cell and Tissue Banking. 2015;16:271–81. doi:10.1007/s10561-014-9459-4. PMID:24929994.
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncology. 2009;10:459–66. doi:10.1016/S1470-2045(09)70025-7. PMID:19269895.
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. New England Journal of Medicine. 2005;352:997–1003. doi:10.1056/NEJMoa043331. PMID:15758010.
   PubMed Web of Science ®Google Scholar
• Weyhenmeyer BC, Noonan J, Wurstle ML, Lincoln FA, Johnston G, Rehm M, Murphy BM. Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide. Oncotarget. 2016;7:61295–311. doi:10.18632/oncotarget.10973. PMID:27494880.
   PubMed Web of Science ®Google Scholar
• Nagel ZD, Kitange GJ, Gupta SK, Joughin BA, Chaim IA, Mazzucato P, Lauffenburger DA, Sarkaria JN, Samson LD. DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma Multiforme. Cancer Research. 2017;77:198–206. doi:10.1158/0008-5472.CAN-16-1151. PMID:27793847.
   PubMed Web of Science ®Google Scholar
• Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, Weller M, Wick W. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res. 2008;14:2900–8. doi:10.1158/1078-0432.CCR-07-1719. PMID:18483356.
   PubMed Web of Science ®Google Scholar
• Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clinical Cancer Research. 2000;6:2585–97. PMID:10914698.
   PubMed Web of Science ®Google Scholar
• Wickstrom M, Dyberg C, Milosevic J, Einvik C, Calero R, Sveinbjornsson B, Sanden E, Darabi A, Siesjo P, Kool M, et al. Wnt/beta-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance. Nature Communications. 2015;6:8904. doi:10.1038/ncomms9904. PMID:26603103.
   PubMed Web of Science ®Google Scholar
• Huse JT, Holland EC. Targeting brain cancer: Advances in the molecular pathology of malignant glioma and medulloblastoma. Nature Reviews Cancer. 2010;10:319–31. doi:10.1038/nrc2818. PMID:20414201.
   PubMed Web of Science ®Google Scholar
• Rocha CR, Kajitani GS, Quinet A, Fortunato RS, Menck CF. NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells. Oncotarget. 2016;7:48081–92. doi:10.18632/oncotarget.10129. PMID:27344172.
   PubMed Web of Science ®Google Scholar
• Li H, Yuan X, Yan D, Li D, Guan F, Dong Y, Wang H, Liu X, Yang B. Long Non-Coding RNA MALAT1 Decreases the Sensitivity of Resistant Glioblastoma Cell Lines to Temozolomide. Cell Physiol Biochem. 2017;42:1192–201. doi:10.1159/000478917. PMID:28668966.
   PubMed Web of Science ®Google Scholar
• Yu Z, Zhao G, Xie G, Zhao L, Chen Y, Yu H, Zhang Z, Li C, Li Y. Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo. Oncotarget. 2015;6:32930–43. doi:10.18632/oncotarget.5405. PMID:26431379.
   PubMed Web of Science ®Google Scholar
• Zheng HC. The molecular mechanisms of chemoresistance in cancers. Oncotarget. 2017;8(35):59950–59964. doi:10.18632/oncotarget.19048. PMID: 28938696.
   PubMed Web of Science ®Google Scholar
• Lu C, Shervington A. Chemoresistance in gliomas. Molecular and Cellular Biochemistry. 2008;312:71–80. doi:10.1007/s11010-008-9722-8. PMID:18259841.
   PubMed Web of Science ®Google Scholar
• Ahmed N, Abubaker K, Findlay J, Quinn M. Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Current Cancer Drug Targets. 2010;10:268–78. doi:10.2174/156800910791190175. PMID:20370691.
   PubMed Web of Science ®Google Scholar
• Liao H, Bai Y, Qiu S, Zheng L, Huang L, Liu T, Wang X, Liu Y, Xu N, Yan X, et al. MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2. Oncotarget. 2015;6:8914–28. doi:10.18632/oncotarget.3563. PMID:25871397.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zeng S, Ma J, Deng G, Qu Y, Guo C, Shen H. Nestin overexpression in hepatocellular carcinoma associates with epithelial-mesenchymal transition and chemoresistance. J Exp Clin Cancer Res. 2016;35:111. doi:10.1186/s13046-016-0387-y. PMID:27412382.
   PubMed Web of Science ®Google Scholar
• Zhou P, Li B, Liu F, Zhang M, Wang Q, Liu Y, Yao Y, Li D. The epithelial to mesenchymal transition (EMT) and cancer stem cells: Implication for treatment resistance in pancreatic cancer. Molecular Cancer. 2017;16:52. doi:10.1186/s12943-017-0624-9. PMID:28245823.
   PubMed Web of Science ®Google Scholar
• Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nature Reviews Molecular Cell Biology. 2014;15:178–96. doi:10.1038/nrm3758. PMID:24556840.
   PubMed Web of Science ®Google Scholar
• Kong D, Li Y, Wang Z, Sarkar FH. Cancer Stem Cells and Epithelial-to-Mesenchymal Transition (EMT)-Phenotypic Cells: Are They Cousins or Twins? Cancers. 2011;3:716–29. doi:10.3390/cancers30100716. PMID:21643534.
   PubMedGoogle Scholar
• Ksiazkiewicz M, Markiewicz A, Zaczek AJ. Epithelial-mesenchymal transition: A hallmark in metastasis formation linking circulating tumor cells and cancer stem cells. Pathobiology. 2012;79:195–208. doi:10.1159/000337106. PMID:22488297.
   PubMed Web of Science ®Google Scholar
• Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. Journal of Clinical Investigation. 2009;119:1429–37. doi:10.1172/JCI36183.
   PubMed Web of Science ®Google Scholar
• Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nature Reviews Molecular Cell Biology. 2006;7:131–42. doi:10.1038/nrm1835. PMID:16493418.
   PubMed Web of Science ®Google Scholar
• Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nature Reviews Cancer. 2009;9:265–73. doi:10.1038/nrc2620. PMID:19262571.
   PubMed Web of Science ®Google Scholar
• Samatov TR, Tonevitsky AG, Schumacher U. Epithelial-mesenchymal transition: Focus on metastatic cascade, alternative splicing, non-coding RNAs and modulating compounds. Molecular Cancer. 2013;12:107. doi:10.1186/1476-4598-12-107. PMID:24053443.
   PubMed Web of Science ®Google Scholar
• Yang S, Liu Y, Li MY, Ng CSH, Yang SL, Wang S, Zou C, Dong Y, Du J, Long X, et al. FOXP3 promotes tumor growth and metastasis by activating Wnt/beta-catenin signaling pathway and EMT in non-small cell lung cancer. Molecular Cancer. 2017;16:124. doi:10.1186/s12943-017-0700-1. PMID:28716029.
   PubMed Web of Science ®Google Scholar
• Tran HD, Luitel K, Kim M, Zhang K, Longmore GD, Tran DD. Transient SNAIL1 expression is necessary for metastatic competence in breast cancer. Cancer Research. 2014;74:6330–40. doi:10.1158/0008-5472.CAN-14-0923. PMID:25164016.
   PubMed Web of Science ®Google Scholar
• Beerling E, Seinstra D, de Wit E, Kester L, van der Velden D, Maynard C, Schafer R, van Diest P, Voest E, van Oudenaarden A, et al. Plasticity between Epithelial and Mesenchymal States Unlinks EMT from Metastasis-Enhancing Stem Cell Capacity. Cell Reports. 2016;14:2281–8. doi:10.1016/j.celrep.2016.02.034. PMID:26947068.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74. doi:10.1016/j.cell.2011.02.013. PMID:21376230.
   PubMed Web of Science ®Google Scholar
• Yang AD, Fan F, Camp ER, van Buren G, Liu W, Somcio R, Gray MJ, Cheng H, Hoff PM, Ellis LM. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res. 2006;12:4147–53. doi:10.1158/1078-0432.CCR-06-0038. PMID:16857785.
   PubMed Web of Science ®Google Scholar
• Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, Ali S, Abbruzzese JL, Gallick GE, Sarkar FH. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Research. 2009;69:2400–7. doi:10.1158/0008-5472.CAN-08-4312. PMID:19276344.
   PubMed Web of Science ®Google Scholar
• Kajiyama H, Shibata K, Terauchi M, Yamashita M, Ino K, Nawa A, Kikkawa F. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. International Journal of Oncology. 2007;31:277–83. PMID:17611683.
   PubMed Web of Science ®Google Scholar
• Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, Wu CC, LeBleu VS, Kalluri R. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature. 2015;527:525–30. doi:10.1038/nature16064. PMID:26560028.
   PubMed Web of Science ®Google Scholar
• Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong ST, Choi H, El Rayes T, Ryu S, Troeger J, et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature. 2015;527:472–6. doi:10.1038/nature15748. PMID:26560033.
   PubMed Web of Science ®Google Scholar
• Liang SQ, Marti TM, Dorn P, Froment L, Hall SR, Berezowska S, Kocher G, Schmid RA, Peng RW. Blocking the epithelial-to-mesenchymal transition pathway abrogates resistance to anti-folate chemotherapy in lung cancer. Cell Death & Disease. 2015;6:e1824. doi:10.1038/cddis.2015.195.
   PubMed Web of Science ®Google Scholar
• Siebzehnrubl FA, Silver DJ, Tugertimur B, Deleyrolle LP, Siebzehnrubl D, Sarkisian MR, Devers KG, Yachnis AT, Kupper MD, Neal D, et al. The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance. EMBO Molecular Medicine. 2013;5:1196–212. doi:10.1002/emmm.201302827. PMID:23818228.
   PubMed Web of Science ®Google Scholar
• Yi GZ, Liu YW, Xiang W, Wang H, Chen ZY, Xie SD, Qi ST. Akt and beta-catenin contribute to TMZ resistance and EMT of MGMT negative malignant glioma cell line. Journal of the Neurological Sciences. 2016;367:101–6. doi:10.1016/j.jns.2016.05.054. PMID:27423571.
   PubMed Web of Science ®Google Scholar
• Wang L, Zhang J, Wan L, Zhou X, Wang Z, Wei W. Targeting Cdc20 as a novel cancer therapeutic strategy. Pharmacol Ther. 2015;151:141–51. doi:10.1016/j.pharmthera.2015.04.002. PMID:25850036.
   PubMed Web of Science ®Google Scholar
• Wan L, Tan M, Yang J, Inuzuka H, Dai X, Wu T, Liu J, Shaik S, Chen G, Deng J, et al. APC(Cdc20) suppresses apoptosis through targeting Bim for ubiquitination and destruction. Developmental Cell. 2014;29:377–91. doi:10.1016/j.devcel.2014.04.022. PMID:24871945.
   PubMed Web of Science ®Google Scholar
• Fodale V, Pierobon M, Liotta L, Petricoin E. Mechanism of cell adaptation: when and how do cancer cells develop chemoresistance? Cancer Journal. 2011;17:89–95. doi:10.1097/PPO.0b013e318212dd3d.
   PubMed Web of Science ®Google Scholar
• Goellner EM, Grimme B, Brown AR, Lin YC, Wang XH, Sugrue KF, Mitchell L, Trivedi RN, Tang JB, Sobol RW. Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair. Cancer Research. 2011;71:2308–17. doi:10.1158/0008-5472.CAN-10-3213. PMID:21406402.
   PubMed Web of Science ®Google Scholar
• Munoz JL, Rodriguez-Cruz V, Greco SJ, Nagula V, Scotto KW, Rameshwar P. Temozolomide induces the production of epidermal growth factor to regulate MDR1 expression in glioblastoma cells. Mol Cancer Ther. 2014;13:2399–411. doi:10.1158/1535-7163.MCT-14-0011. PMID:25053824.
   PubMed Web of Science ®Google Scholar
• Bhuvanalakshmi G, Arfuso F, Millward M, Dharmarajan A, Warrier S. Secreted frizzled-related protein 4 inhibits glioma stem-like cells by reversing epithelial to mesenchymal transition, inducing apoptosis and decreasing cancer stem cell properties. PloS One. 2015;10:e0127517. doi:10.1371/journal.pone.0127517. PMID:26030909.
   PubMed Web of Science ®Google Scholar
• Li B, Xu WW, Guan XY, Qin YR, Law S, Lee NP, Chan KT, Tam PY, Li YY, Chan KW, et al. Competitive Binding Between Id1 and E2F1 to Cdc20 Regulates E2F1 Degradation and Thymidylate Synthase Expression to Promote Esophageal Cancer Chemoresistance. Clin Cancer Res. 2016;22:1243–55. doi:10.1158/1078-0432.CCR-15-1196. PMID:26475334.
   PubMed Web of Science ®Google Scholar
• Li XX, Zheng HT, Peng JJ, Huang LY, Shi DB, Liang L, Cai SJ. RNA-seq reveals determinants for irinotecan sensitivity/resistance in colorectal cancer cell lines. Int J Clin Exp Pathol. 2014;7:2729–36. PMID:24966994.
   PubMed Web of Science ®Google Scholar
• Nasr T, Bondock S, Youns M. Anticancer activity of new coumarin substituted hydrazide-hydrazone derivatives. Eur J Med Chem. 2014;76:539–48. doi:10.1016/j.ejmech.2014.02.026. PMID:24607878.
   PubMed Web of Science ®Google Scholar
• Mao DD, Gujar AD, Mahlokozera T, Chen I, Pan Y, Luo J, Brost T, Thompson EA, Turski A, Leuthardt EC, et al. A CDC20-APC/SOX2 Signaling Axis Regulates Human Glioblastoma Stem-like Cells. Cell Reports. 2015;11:1809–21. doi:10.1016/j.celrep.2015.05.027. PMID:26074073.
   PubMed Web of Science ®Google Scholar
• Li S, Zhang X, Zhang R, Liang Z, Liao W, Du Z, Gao C, Liu F, Fan Y, Hong H. Hippo pathway contributes to cisplatin resistant-induced EMT in nasopharyngeal carcinoma cells. Cell Cycle. 2017;16:1601–10. doi:10.1080/15384101.2017.1356508. PMID:28749195.
   PubMed Web of Science ®Google Scholar
• Wang L, Hou Y, Yin X, Su J, Zhao Z, Ye X, Zhou X, Zhou L, Wang Z. Rottlerin inhibits cell growth and invasion via down-regulation of Cdc20 in glioma cells. Oncotarget. 2016;7:69770–82. PMID:27626499.
   PubMed Web of Science ®Google Scholar